New antibody drug aims to quiet artery inflammation in heart disease patients
NCT ID NCT06572267
First seen Jan 27, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This study tests a drug called meplazumab in 18 adults with coronary artery disease (narrowed heart arteries). The drug targets inflammation in artery plaques, which may help slow disease progression. Participants receive the drug or a placebo for several months, and doctors use CT scans and blood tests to measure changes in plaque and inflammation. The goal is to see if the drug is safe and can reduce artery inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ling Tao
RECRUITINGXi'an, Shannxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.